Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Merkel Cell 2Uveal Melanoma 1Ovarian Neoplasms 1Melanoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Brain Neoplasms 1Astrocytoma 1Adenoviridae Infections 1

Interventions

Temozolomide 130Radiotherapy 86Bevacizumab 43Radiation 31Carmustine 29Irinotecan 22Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gefitinib 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gliosarcoma × Interferon-beta × Clear all
NCT00031083 2020-11-17

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

Biogen

Phase 1 Completed
12 enrolled
CNSSarcoma

Adenoviridae Infections, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡